[ad_1]
According to preliminary phase 1-2 results published in The Lancet Infectious Diseases, the trial is giving good answers. More than 600 healthy volunteers between 18 and 80 years old participated. Precisely “the protection of the elderly is a key objective for an effective anti-Covid vaccine since this group is at greater risk
Encouraging news from China on the Covid-19 vaccine front (LATEST NEWS LIVE). Preliminary results of the phase 1-2 trial of the antidote candidate BBIBP-CorV showed that the Chinese vaccine, developed using all of the inactivated Sars-Cov-2 virus, was safe and was shown to induce an immune response in healthy volunteers. During the trial, conducted in China from April 29 to July 30, 2020 by various health institutions in the country, including the Henan Provincial Center for Disease Control and Prevention and the Beijing Institute of Biological Products, more than 600 volunteers healthy aged between 18 and 80 years. The study, described in detail in the pages of the specialized journal The Lancet Infectious Diseases, showed an antibody response in all participants within day 42 of vaccination.
The preliminary results of the first stages of experimentation.
deepening
Covid, 80 experts reject herd immunity: “It does not stop the virus”
“Protecting the elderly is a key goal for an effective Covid vaccine, as this group is most at risk. Therefore, it is encouraging that this vaccine induces antibody responses even in people aged 60 years and older,” he commented Xiaoming Yang, among the study authors. Specifically, preliminary results from the phase 1-2 trial showed that volunteers older than 60 years took longer to develop antibodies to Covid-19 than the rest of the sample. On average, the antibody response in those older than 60 years developed 42 days after vaccination, compared with 28 days for younger volunteers. In addition, the study found that antibody levels were lower among those over 60, compared to those younger. However, “vaccines are sometimes less effective in older people and this is because the immune system weakens with age. The results of this vaccine candidate in older people are therefore encouraging and should be explored. more thoroughly, “he commented. Xiaoming Yang of the Institute of Biological Products of Beijing Company Limited.
The phase 1-2 study is not about the efficacy of the vaccine
However, the authors note that the efficacy of the vaccine was not evaluated during the phase 1-2 trial: “Therefore, it is not possible to say whether the vaccine-induced antibody response is sufficient to protect against Sars-Cov. – two “. Further details on the results of phase 3 will be obtained. The candidate antidote BBIBP-CorV is based on a sample of the virus isolated from a Chinese patient and includes the Sars-Cov-2 virus and aluminum hydroxide, known to enhance the immune response .
